pok-f

«“√ “√ √“™∫— ≥±‘ µ¬ ∂“π ªï ∑’Ë ÛÛ ©∫— ∫∑’Ë Ú ‡¡.¬..-¡‘ .¬. ÚııÒ 81 π‘ ¿“ ®√Ÿ ≠‡« ¡å high-risk patients. N Eng J Med 2003 ; 342 : 145-53. (ÙÛ) Dahlof B, Devereux RB,Kjeldsen SE, et al. Cardiovascular morbidity and mortal- ity in the Losartan Intervention For End- point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002 ; 362 : 1527-35. (ÙÙ)Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the Fat cell „Àâ Adepokine Adeponectin - À≠‘ ß ¡’ > ™“¬ ¢Õß√à “ß°“¬·≈–À≈Õ¥‡≈◊ Õ¥ - ∑”„Àâ À≈Õ¥‡≈◊ Õ¥Õÿ ¥µ— π À¡¥ª√–®”‡¥◊ Õπ - §«∫§ÿ ¡ ¡¥ÿ ≈µà “ßÊ ¢Õß√à “ß°“¬ - §«∫§ÿ ¡ metabolism ¢Õß°≈Ÿ ‚§ , ‰¢¡— π„π‡´≈≈å µ— ∫, ‡´≈≈å °≈â “¡‡π◊È Õ≈“¬ ·≈– fat cell - ™à «¬„Àâ √à “ß°“¬‰«µà ÕÕ‘ π´Ÿ ≈‘ π - ≈¥°“√º≈‘ µ°≈Ÿ ‚§ ·≈–°“√∑”ß“π¢ÕßÕ‘ π´Ÿ ≈‘ π∑’Ë µ— ∫ - ≈¥°“√ – ¡‰µ√°≈’ ‡´Õ‰√¥å ∑’Ë °≈â “¡‡π◊È Õ≈“¬ - ¬— ∫¬—È ß°√–∫«π°“√Õ— °‡ ∫‚¥¬¬— ∫¬—È ß°“√º≈‘ µ TNF α ®“° macrophage “¡“√∂µâ “π°“√ ‡°‘ ¥‚√§À≈Õ¥‡≈◊ Õ¥À— «„®‰¥â - ¬— ∫¬—È ß°“√ √â “ß°≈Ÿ ‚§ ®“° “√∑’Ë ‰¡à „™à §“√å ‚∫‰Œ‡¥√µ VALUE randomized trial. Lancet 2004 ; 363 : 2022-31. (Ùı) Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with hypertension-2 study. Lancet 1999 ; 1751 - 6. (Ùˆ)The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002 ; 346 : 393 - 403. (Ù˜)Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type Ú dia- betes mellitus : The STOP-NIDDN ran- domize trial. Lancel 2002 ; 359 : 2072- 7. (Ù¯)Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovas- cular disease in paitents with type Ú diabetes. N Eng J Med 2003 ; 348 : 383-93. §πÕâ «π‡°‘ π - ¡’ adeponectin µË ”°«à “§πª√°µ‘ - adeponectin µË ” — ¡æ— π∏å °— ∫°“√ Ÿ ≠‡ ’ ¬°“√∑”ß“π ¢Õß β cell ¢Õßµ— ∫Õà Õπ∑’Ë √â “ßÕ‘ π´Ÿ ≈‘ π ➔ DM Type II - ¡’ §«“¡‰«µà ÕÕ‘ π´Ÿ ≈‘ π ≈¥≈ß - ¡’ TNF- α Ÿ ß°«à “§πª√°µ‘ ´÷Ë ß — ¡æ— π∏å °— ∫ BMI , √–¥— ∫πÈ ”µ“≈·≈–√–¥— ∫‰µ√°≈’ ‡´Õ‰√¥å Tumor Necrosis Factor - α - ∑”„Àâ ‡°‘ ¥°“√Õ— °‡ ∫¢Õ߇π◊È Õ‡¬◊Ë Õ - À≠‘ ß ª√°µ‘ > À≠‘ ß - ≈¥°“√ √â “ß adeponectin ‡æ√“–®–≈¥√–¥— ∫°“√ · ¥ßÕÕ°¢Õ߬’ π¢Õß adeponectin - ‡´≈≈å ‰¢¡— πÀ≈—Ë ß°√¥‰¢¡— π¡“°¢÷È π - ∑”„Àâ ‡´≈≈å µà “ßÊ ‡æ‘Ë ¡¿“«–¥◊È ÕÕ‘ π´Ÿ ≈‘ π °“√ à ß — ≠≠“≥¢ÕßÕ‘ π´Ÿ ≈‘ π∫°æ√à Õß